Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA.
Department of Radiology, University of Michigan, Ann Arbor, MI, USA.
Interv Neuroradiol. 2021 Jun;27(3):353-361. doi: 10.1177/1591019921989476. Epub 2021 Jan 28.
The Neuroform Atlas stent is thought to have features allowing for an improved stent delivery system. We aimed to provide a comparison of the Atlas and Neuroform EZ stents in patients treated with stent-assisted coiling.
Seventy-seven aneurysms treated with the Atlas stent and 77 aneurysms with similar characteristics treated with the EZ stent were retrospectively compared. Outcomes included angiographic occlusion per the Raymond-Roy (RR) scale, recanalization, retreatment and procedural complications.
With the Atlas stent, technical success was 100% and immediate RR1 occlusion was 81.8%. Follow-up RR1 was achieved in 83.7%. The recanalization rate was 7% and the retreatment rate was 4.6%. The complication rate was 6.5% (new neurological deficit in 1.3%). With the EZ stent, technical success was 96%, immediate RR1 occlusion was 67.6% and follow-up RR1 was 67.6%. The recanalization rate was 12.7% and the retreatment rate was 14.1%. The complication rate was 10.4% (new neurological deficit in 2.6%). The rate of immediate RR1 occlusion was significantly higher with the Atlas stent ( = 0.03), and the rate of follow-up RR1 was nonsignificantly higher with the Atlas stent ( = 0.08). The retreatment rate was significantly lower with the Atlas stent ( = 0.009). There were no significant differences in the rates of recanalization ( = 0.5) and complications ( = 0.6).
Stent-assisted coiling with the Atlas stent is safe and effective and shows better immediate results as compared to the EZ stent, with improved overall follow-up outcomes.
Neuroform Atlas 支架被认为具有改进的支架输送系统的特点。我们旨在比较 Atlas 支架和 Neuroform EZ 支架在接受支架辅助弹簧圈治疗的患者中的应用。
回顾性比较了 77 例使用 Atlas 支架治疗的动脉瘤和 77 例具有相似特征的使用 EZ 支架治疗的动脉瘤。结果包括根据 Raymond-Roy（RR）分级的血管造影闭塞、再通、再治疗和程序并发症。
使用 Atlas 支架，技术成功率为 100%，即刻 RR1 闭塞率为 81.8%。随访时达到 RR1 闭塞率为 83.7%。再通率为 7%，再治疗率为 4.6%。并发症发生率为 6.5%（新的神经功能缺损发生率为 1.3%）。使用 EZ 支架，技术成功率为 96%，即刻 RR1 闭塞率为 67.6%，随访时 RR1 闭塞率为 67.6%。再通率为 12.7%，再治疗率为 14.1%。并发症发生率为 10.4%（新的神经功能缺损发生率为 2.6%）。Atlas 支架即刻 RR1 闭塞率显著高于 EZ 支架（=0.03），而 Atlas 支架随访时 RR1 闭塞率无显著差异（=0.08）。Atlas 支架的再治疗率显著较低（=0.009）。再通率（=0.5）和并发症发生率（=0.6）无显著差异。
与 EZ 支架相比，Atlas 支架辅助弹簧圈治疗安全有效，即刻结果更好，总体随访结果更佳。
